KLK6 and early-onset autosomal dominant Alzheimer disease: Downregulated serum levels of this biomarker predicted cognitive and motor declines in patients with Parkinson disease [36], Last, plasma levels of the neuroinflammation modulator KLK6 were significantly increased in patients with advanced Alzheimer disease compared with healthy controls [37].